The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.
VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.
AAN 2026 | The clinical potential of orexin-2 receptor agonists across sleep disorders
Bruce Corser, MD, FAASM, Intrepid Research, Cincinnati, OH, discusses the clinical potential of orexin-2 receptor agonists across sleep disorders. Dr Corser highlights their expected impact in transforming treatment for narcolepsy, particularly type 1, with emerging evidence also supporting use in type 2 narcolepsy and idiopathic hypersomnia. This interview took place at the 78th American Academy of Neurology (AAN) Annual Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, orexin-2 agonists are going to be remarkably effective for people with type 1 narcolepsy. What we have seen is that typically the doses for type 2 narcolepsy are about four times higher to achieve the same therapeutic benefit. In addition, people with idiopathic hypersomnia may also benefit from this type of medicine. So both NT2, that is type 2 narcolepsy, as well as idiopathic hypersomnia, cohorts are being investigated for these agents...
So, orexin-2 agonists are going to be remarkably effective for people with type 1 narcolepsy. What we have seen is that typically the doses for type 2 narcolepsy are about four times higher to achieve the same therapeutic benefit. In addition, people with idiopathic hypersomnia may also benefit from this type of medicine. So both NT2, that is type 2 narcolepsy, as well as idiopathic hypersomnia, cohorts are being investigated for these agents. But this will substantially change the landscape in terms of allowing people to have a really much more effective therapeutic option that is currently available. I think this will eventually replace most of the daytime wake-promoting agents or stimulants for the treatment of narcolepsy, especially type 1, but also probably type 2.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Dr. Corser has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Axsome. Dr. Corser has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Avadel. The institution of Dr. Corser has received research support from Alkermes, . The institution of Dr. Corser has received research support from Apnimed. The institution of Dr. Corser has received research support from Avadel. The institution of Dr. Corser has received research support from Axsome. The institution of Dr. Corser has received research support from Eisai. The institution of Dr. Corser has received research support from Eli Lilly. The institution of Dr. Corser has received research support from Harmony. The institution of Dr. Corser has received research support from Incannex. The institution of Dr. Corser has received research support from Jazz. The institution of Dr. Corser has received research support from Mineralys. The institution of Dr. Corser has received research support from Suven. The institution of Dr. Corser has received research support from Takeda. The institution of Dr. Corser has received research support from Centessa. The institution of Dr. Corser has received research support from Bayer. The institution of Dr. Corser has received research support from Beacon Biosignal .
